Lung squamous cell carcinoma stage III

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Antimetabolite 2 substances
Platinum compound 1 substance
Monoclonal antibody (primate) 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • Summit Therapeutics Inc. Commercial
    CARBOPLATIN; IVONESCIMAB; PEMETREXED; PEMETREXED DISODIUM
    2023-504434-22-00 3 countries 2023 n=45
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Summit Therapeutics Inc. Commercial 1 Phase III 0
New trials by year
2023
1
← All indication landscapes